Anergis SA of Switzerland, which is developing allergy vaccines, has announced the appointment of Gilles Della Corte to the position of director of clinical development. The appointment, which became effective on 3 January, comes ahead of Phase 2 data from the company’s lead product which is expected in the third quarter. Dr Della Corte, a medical doctor, trained as a cardiologist and pharmacologist. He has worked for several large pharmaceutical companies including Rhone-Poulenc Rorer, Servier, Solvay Parma, Serono and Merck Serono.
Also on the management team is Eva Castagnetti who joined Anergis in November 2012 as director of product development. She has worked in both technical and management functions at Lonza, Senn Chemicals AG and Rapid Pharmaceuticals Inc. She has a PhD in organic chemistry from the University of Lausanne/EPFL and spent two years as a postdoctoral fellow at the Massachusetts Institute of Technology and at the ETH in Zurich.
Anergis announced the appointments on 14 February 2014.
Copyright 2013 Evernow Publishing Ltd.